A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).

Julie Delyon,Raphaël Porcher,Maxime Battistella,Nicolas Meyer,H. Adamski,François Bertucci,B. Guillot,Thomas Jouary,Marie Thérèse Leccia,S. Dalac,L. Mortier,Laetitia Da Meda,Eric Vicaut,Florence Pedeutour,Samia Mourah,Celeste Lebbe

A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).

2018

Julie Delyon
Raphaël Porcher
Maxime Battistella
Nicolas Meyer
H. Adamski
François Bertucci
B. Guillot
Thomas Jouary
Marie Thérèse Leccia
S. Dalac
L. Mortier
Laetitia Da Meda
Eric Vicaut
Florence Pedeutour
Samia Mourah
Celeste Lebbe

11557Background: DFSP is a tumor accounting for 6% of soft-tissue sarcoma, with a high risk of local infiltrative dissemination. Wide local excision is the standard treatment. The identification of...

Keywords:

Pazopanib
General surgery
Dermatofibrosarcoma protuberans
Pathology
Medicine
Phases of clinical research
Wide local excision
Standard treatment
in patient
Radiology
Sarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations